F. Hoffmann-La Roche Ltd. - Product Pipeline Review - 2016

Date: March 16, 2016
Pages: 327
Price:
US$ 1,500.00 US$ 1,275.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: HCB7FB4256AEN
Leaflet:

Download PDF Leaflet

F. Hoffmann-La Roche Ltd. - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘F. Hoffmann-La Roche Ltd. - Product Pipeline Review - 2016’, provides an overview of the F. Hoffmann-La Roche Ltd.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by F. Hoffmann-La Roche Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the pipeline therapeutic landscape of F. Hoffmann-La Roche Ltd.
  • The report provides overview of F. Hoffmann-La Roche Ltd. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses F. Hoffmann-La Roche Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features F. Hoffmann-La Roche Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate F. Hoffmann-La Roche Ltd.’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for F. Hoffmann-La Roche Ltd.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding F. Hoffmann-La Roche Ltd.’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
F. Hoffmann-La Roche Ltd. Snapshot
F. Hoffmann-La Roche Ltd. Overview
Key Information
Key Facts
F. Hoffmann-La Roche Ltd. - Research and Development Overview
Key Therapeutic Areas
F. Hoffmann-La Roche Ltd. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Pipeline Products - Out-Licensed Products
F. Hoffmann-La Roche Ltd. - Pipeline Products Glance
F. Hoffmann-La Roche Ltd. - Late Stage Pipeline Products
F. Hoffmann-La Roche Ltd. - Clinical Stage Pipeline Products
F. Hoffmann-La Roche Ltd. - Early Stage Pipeline Products
F. Hoffmann-La Roche Ltd. - Drug Profiles
alectinib
atezolizumab
bevacizumab
obinutuzumab
omalizumab
rituximab
alteplase
emicizumab
gantenerumab
idasanutlin
lebrikizumab
ocrelizumab
onartuzumab
pertuzumab
ranibizumab
tocilizumab
trastuzumab emtansine
vemurafenib
olesoxime
(danoprevir + ritonavir)
basimglurant
basmisanil
cobimetinib fumarate
codrituzumab
danoprevir
emactuzumab
miravirsen
RG-7314
RG-7716
RG-7795
RG-7800
RO-5093151
RO-6864018
TRX-1
vanucizumab
RG-6016
cergutuzumab amunaleukin
DCDS-0780A
lumretuzumab
OP-0595
PRX-002
RG-4929
RG-6061
RG-6069
RG-6078
RG-6125
RG-7304
RG-7386
RG-7461
RG-7625
RG-7775
RG-7802
RG-7834
RG-7876
RG-7880
RG-7916
RG-7944
RG-7986
RG-7992
RO-6799477
RO-6806127
RO-6836191
RO-6870868
RO-6874281
RO-6874813
RO-6889678
RO-7020322
RO-7033877
vismodegib
Antisense Oligonucleotide to Target miR-33 for Cardiovascular Diseases
CLP-257
GAL-F2
Gene Therapy to Activate Telomerase for Aplastic Anemia
IMA-930
IMA-942
IMA-962
ITMN-10534
ITMN-14440
ITMN-30162
Monoclonal Antibody Conjugates for Solid Tumor
Monoclonal Antibody to Inhibit RSV-G and RSV-F for RSV Infections
Monoclonal Antibody to Inhibit VEGF-A for Ophthalmology
RN-486
RO-2959
RO-4938581
RO-5073012
RO-5203280
RO-5461111
RO-646198
RO-6839328
RO-6889450
RO-9021
Small Molecule 2 to Inhibit XIAP for Oncology
Small Molecule to Agonize GPR119 for Type II Diabetes
Small Molecule to Inhibit XIAP for Oncology
Small Molecules for Myotonic Dystrophy Type
Small Molecules to Inhibit ERG for Prostate Cancer
Small Molecules to Inhibit Janus Kinase 3 for Inflammation
Small Molecules to Inhibit PTP1B for Obesity and Diabetes
Small Molecules to Inhibit Viral RNA Polymerase for Influenza
XGFR-2
XGFR-4
Monoclonal Antibodies for Cancer
RG-7109
RO-5454948
RO-8994
Small Molecule to Activate Glycogen Synthase for Type 2 Diabetes
Small Molecule to Inhibit LOXL2 for Fibrosis
Small Molecule to Inhibit NS5B for Hepatitis C
Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections
Small Molecules for Neuropsychiatric Disorders
Small Molecules to Antagonize LPA1 Receptor for Pulmonary Fibrosis
F. Hoffmann-La Roche Ltd. - Pipeline Analysis
F. Hoffmann-La Roche Ltd. - Pipeline Products by Target
F. Hoffmann-La Roche Ltd. - Pipeline Products by Route of Administration
F. Hoffmann-La Roche Ltd. - Pipeline Products by Molecule Type
F. Hoffmann-La Roche Ltd. - Pipeline Products by Mechanism of Action
F. Hoffmann-La Roche Ltd. - Recent Pipeline Updates
F. Hoffmann-La Roche Ltd. - Dormant Projects
F. Hoffmann-La Roche Ltd. - Discontinued Pipeline Products
F. Hoffmann-La Roche Ltd. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
F. Hoffmann-La Roche Ltd. - Company Statement
F. Hoffmann-La Roche Ltd. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

F. Hoffmann-La Roche Ltd., Key Information
F. Hoffmann-La Roche Ltd., Key Facts
F. Hoffmann-La Roche Ltd. - Pipeline by Indication, 2016
F. Hoffmann-La Roche Ltd. - Pipeline by Stage of Development, 2016
F. Hoffmann-La Roche Ltd. - Monotherapy Products in Pipeline, 2016
F. Hoffmann-La Roche Ltd. - Combination Treatment Modalities in Pipeline, 2016
F. Hoffmann-La Roche Ltd. - Partnered Products in Pipeline, 2016
F. Hoffmann-La Roche Ltd. - Partnered Products/ Combination Treatment Modalities, 2016
F. Hoffmann-La Roche Ltd. - Out-Licensed Products in Pipeline, 2016
F. Hoffmann-La Roche Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2016
F. Hoffmann-La Roche Ltd. - Pre-Registration, 2016
F. Hoffmann-La Roche Ltd. - Filing rejected/Withdrawn, 2016
F. Hoffmann-La Roche Ltd. - Phase III, 2016
F. Hoffmann-La Roche Ltd. - Phase II, 2016
F. Hoffmann-La Roche Ltd. - Phase I, 2016
F. Hoffmann-La Roche Ltd. - Preclinical, 2016
F. Hoffmann-La Roche Ltd. - Discovery, 2016
F. Hoffmann-La Roche Ltd. - Pipeline by Target, 2016
F. Hoffmann-La Roche Ltd. - Pipeline by Route of Administration, 2016
F. Hoffmann-La Roche Ltd. - Pipeline by Molecule Type, 2016
F. Hoffmann-La Roche Ltd. - Pipeline Products by Mechanism of Action, 2016
F. Hoffmann-La Roche Ltd. - Recent Pipeline Updates, 2016
F. Hoffmann-La Roche Ltd. - Dormant Developmental Projects,2016
F. Hoffmann-La Roche Ltd. - Discontinued Pipeline Products, 2016
F. Hoffmann-La Roche Ltd., Subsidiaries

LIST OF FIGURES

F. Hoffmann-La Roche Ltd. - Pipeline by Top 10 Indication, 2016
F. Hoffmann-La Roche Ltd. - Pipeline by Stage of Development, 2016
F. Hoffmann-La Roche Ltd. - Monotherapy Products in Pipeline, 2016
F. Hoffmann-La Roche Ltd. - Partnered Products in Pipeline, 2016
F. Hoffmann-La Roche Ltd. - Out-Licensed Products in Pipeline, 2016
F. Hoffmann-La Roche Ltd. - Pipeline by Top 10 Target, 2016
F. Hoffmann-La Roche Ltd. - Pipeline by Route of Administration, 2016
F. Hoffmann-La Roche Ltd. - Pipeline by Top 10 Molecule Type, 2016
F. Hoffmann-La Roche Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016
Skip to top


AnaptysBio, Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Apr, 2015 · 24 pages
Dystonia - Pipeline Review, H2 2016 US$ 2,000.00 Oct, 2016 · 45 pages
OncoEthix SA - Product Pipeline Review - 2014 US$ 1,125.00 Jun, 2014 · 21 pages
Myocardial Fibrosis - Pipeline Review, H1 2016 US$ 2,000.00 Jun, 2016 · 82 pages

Ask Your Question

F. Hoffmann-La Roche Ltd. - Product Pipeline Review - 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: